Outlook Therapeutics: Q3 Earnings Insights

Shares of Outlook Therapeutics OTLK moved higher by 2.8% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were down 133.33% year over year to ($0.07), which were in line with the estimate of ($0.07).

Revenue of $0 unchanged by 0.00% year over year, which missed the estimate of $320,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Recent Stock Performance

52-week high: $4.26

Company's 52-week low was at $0.58

Price action over last quarter: Up 15.56%

Company Profile

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.